11 Things General Practitioners Still Get Wrong About Menopause That Are Directly Harming Women
The number of women who've been handed an antidepressant prescription when they asked about their periods changing — and then spent years wondering why they still felt awful — is not a small number. If something about your care hasn't felt right, it probably wasn't. You weren't being dramatic, and you weren't imagining it.
Learn more about Rose →Treating the WHI study as the final word on HRT safety
The 2002 Women's Health Initiative trial caused a mass exodus from hormone therapy, but subsequent re-analysis revealed critical flaws: participants had an average age of 63, were years post-menopause, and many had pre-existing cardiovascular risk factors. When HRT is initiated within ten years of menopause or before age 60 — the so-called 'timing hypothesis' or 'window of opportunity' — the cardiovascular and mortality data look substantially different. Applying blanket WHI conclusions to a 47-year-old in early perimenopause is not evidence-based medicine; it is outdated medicine.
Diagnosing depression when the real driver is hormonal disruption
Fluctuating estrogen directly modulates serotonin, dopamine, and norepinephrine pathways, meaning perimenopausal women can present with all the clinical hallmarks of a depressive episode without having a primary mood disorder. A GP who prescribes an SSRI without considering the hormonal context may provide partial relief at best — and for some women, antidepressants alone do little while the underlying estrogen volatility continues unchecked. The NICE menopause guideline explicitly states that HRT should be considered for low mood arising in the context of perimenopause, yet this recommendation is widely under-applied in primary care.
Dismissing perimenopause because FSH levels are 'normal'
Follicle-stimulating hormone levels fluctuate wildly during perimenopause — a woman can have a high FSH one week and a normal reading the next, depending on where she is in an erratic cycle. Using a single FSH reading to rule out perimenopause in a woman under 45 with classic symptoms is a well-documented clinical error that delays diagnosis by months or years. Both NICE and the British Menopause Society are explicit that perimenopause is a clinical diagnosis in women over 45, based on symptoms, not blood tests.
Underestimating genitourinary syndrome of menopause as 'just dryness'
Genitourinary syndrome of menopause (GSM) encompasses vaginal atrophy, urethral changes, recurrent UTIs, painful sex, urinary urgency, and altered microbiome — it is a chronic, progressive condition that worsens without estrogen and does not resolve on its own. Many GPs offer a single tube of over-the-counter lubricant and consider the matter closed, when the evidence strongly supports the use of local vaginal estrogen as a safe, effective, long-term treatment — including for women with a history of breast cancer in many cases. Undertreated GSM has measurable impacts on quality of life, relationships, and urinary health, and it deserves the same clinical seriousness as any other chronic condition.
Failing to connect sleep disruption to hormonal change
Insomnia and non-restorative sleep are among the most commonly reported perimenopausal symptoms, driven by declining progesterone (which has GABAergic, sleep-promoting properties) and the nocturnal cortisol spikes triggered by hot flashes. GPs routinely offer sleep hygiene advice or short-term hypnotics without addressing the hormonal root cause — which means the sleep disruption continues, along with its downstream effects on metabolism, cognition, mood, and cardiovascular health. Progesterone, particularly micronised oral progesterone taken at night, has a meaningful body of evidence supporting its role in improving sleep quality in perimenopausal women.
Telling women they are 'too young' for perimenopause without investigation
Perimenopause can begin in a woman's late 30s, and premature ovarian insufficiency (POI) affects roughly 1 in 100 women under 40 — yet women in this age group are routinely told their symptoms cannot possibly be hormonal. This delay is not benign: POI carries significant long-term risks for bone density, cardiovascular health, and cognitive function that are substantially mitigated by HRT, and every year without a diagnosis is a year of preventable risk accumulation. Any woman under 40 presenting with cycle changes, vasomotor symptoms, or unexplained mood shifts deserves prompt investigation, not reassurance that she is simply stressed.
Overstating breast cancer risk from HRT without contextualising absolute numbers
The relative risk increase associated with combined HRT is frequently communicated to women in a way that sounds far more alarming than the absolute numbers warrant — an increase from roughly 23 to 26 cases per 1,000 women over five years is a very different proposition than 'it increases your breast cancer risk.' Meanwhile, the protective effects of HRT on cardiovascular disease, osteoporosis, type 2 diabetes, and all-cause mortality are rarely given equivalent weight in those same conversations. Women deserve a balanced, numerically honest risk-benefit discussion — not a conversation shaped primarily by fear of one outcome.
Missing the link between perimenopausal brain fog and estrogen withdrawal
Estrogen has well-established neuroprotective and cognitive roles — it supports cerebral blood flow, synaptic plasticity, and the synthesis of acetylcholine, a neurotransmitter central to memory and attention. The word-finding difficulties, concentration lapses, and mental fatigue that women describe during perimenopause are not imaginary, not aging, and not early dementia — they are measurable cognitive changes associated with estrogen fluctuation. Sending women for dementia screening before considering the hormonal context is a significant clinical failure that causes enormous and unnecessary psychological distress.
Prescribing combined oral contraceptives as a 'fix' that hides the diagnostic picture
Putting a perimenopausal woman on the combined oral contraceptive pill may regulate bleeding and suppress hot flashes, but it also suppresses the hormonal fluctuations that would otherwise signal where she is in the transition — and it provides a synthetic estrogen profile that is pharmacologically quite different from HRT. Women on the pill in their late 40s are often told they cannot know if they have reached menopause, which delays appropriate transition to evidence-based menopausal management. The pill is not wrong for every woman in this group, but using it as a substitute for a perimenopause conversation is a missed clinical opportunity.
Ignoring cardiovascular risk as a primary reason to consider HRT
Heart disease is the leading cause of death in postmenopausal women, and estrogen loss is directly implicated in the acceleration of atherosclerosis, adverse lipid shifts, increased arterial stiffness, and central fat redistribution that follows menopause. When HRT is initiated within the window of opportunity, the evidence for cardiovascular benefit — or at minimum, no harm — in healthy younger postmenopausal women is substantial. GPs who frame HRT purely as a quality-of-life intervention for hot flashes are leaving the most compelling long-term health argument off the table entirely.
Stopping HRT at age 60 based on habit rather than individual assessment
There is no evidence-based universal age at which HRT must be stopped, yet many GPs routinely withdraw it at 60 — or after five years — citing guidelines that do not actually mandate this. For women who are benefiting, have no contraindications, and have had a proper informed risk-benefit discussion, continuing HRT beyond 60 is a clinically legitimate and increasingly supported choice. The Menopause Society and the British Menopause Society both state that duration of use should be an individualised decision, not a default withdrawal based on an arbitrary birthday.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.